Breaking News Instant updates and real-time market news.

HZNP

Horizon Pharma

$19.52

0.79 (4.22%)

, ESRX

Express Scripts

$70.57

0.51 (0.73%)

09:01
10/11/16
10/11
09:01
10/11/16
09:01

Horizon Pharma sees Q3 adjusted net sales of $272M-$274M, consensus $271.5M

Horizon Pharma (HZNP) estimates, on a GAAP basis including the previously announced $65M settlement with Express Scripts (ESRX) as a one-time reduction in GAAP net sales, its third-quarter 2016 net sales were in the range of $207M-$209M. The company estimates that non-GAAP adjusted net sales, which exclude the $65M settlement with Express Scripts, were in the range of $272M-$274M. The exclusion of the $65 million settlement from GAAP net sales is the only adjustment reflected in third-quarter non-GAAP adjusted net sales. The company expects that Q3 adjusted EBITDA will be in the range of $139M-$141M, which would represent an adjusted EBITDA margin of approximately 51% and sequential quarterly growth versus the second quarter of 2016 of approximately 15%. The company will provide additional information on its Q3 earnings conference call scheduled for November 7.

HZNP

Horizon Pharma

$19.52

0.79 (4.22%)

ESRX

Express Scripts

$70.57

0.51 (0.73%)

  • 26

    Oct

  • 06

    Nov

  • 14

    Dec

HZNP Horizon Pharma
$19.52

0.79 (4.22%)

08/02/16
BMOC
08/02/16
NO CHANGE
BMOC
Outperform
Horizon Pharma scored 'important win' with CVS, says BMO Capital
BMO Capital analyst Gary Nachman said Horizon Pharma (HZNP) securing covered status for Duexis and Vimovo with CVS/Caremark (CVS) is an "important win" for the drugmaker that demonstrates it is improving its execution on the managed care front. While Express Scripts (ESRX) still has Duexis and Vimovo on its exclusion list for 2017, Horizon indicated that it is still in discussions that have been "constructive," noted Nachman, who keeps an Outperform rating on Horizon shares.
09/13/16
BMUR
09/13/16
NO CHANGE
Target $32
BMUR
Buy
Horizon Pharma acquisition a positive, says Brean Capital
Brean Capital analyst Difei Yang said she is positive on Horizon Pharma's (HZNP) deal for Raptor Pharmaceuticals (RPTP). The analyst cited Horizon executing on its transformative strategy into an orphan disease company, the reasonable price paid for the company, and the moderate growth opportunities for synergies between the two. Yang reiterated her Buy rating and raised her price target to $32 from $30 on Horizon Pharma shares.
09/30/16
JMPS
09/30/16
NO CHANGE
JMPS
Horizon Pharma patent loss immaterial, says JMP Securities
After the U.S. Patent and Trademark Office ruled that Horizon Pharma's '215 patent for Ravicti is unpatentable, JMP Securities analyst Donald Ellis says the news is not material. He says that Ravicti still has orphan drug exclusivity until 2020, and that the company has five other patents on the drug that will last until 2032. He recommends buying Horizon on any weakness.
10/03/16
BMOC
10/03/16
NO CHANGE
BMOC
Horizon Pharma added to US Small Cap Fundamental List at BMO Capital
ESRX Express Scripts
$70.57

0.51 (0.73%)

08/09/16
LEER
08/09/16
NO CHANGE
Target $110
LEER
Outperform
Leerink remains positive on CVS Health long-term fundamentals
Leerink analyst David Larsen continues to be positive on CVS' (CVS) long-term fundamentals. The analyst notes that the company is having a successful 2017 selling season, with a retention rate higher than what it was last year, and says its Q3 should benefit from a number of break-even generics. Further, Larsen says the company is being more aggressive than Express Scripts (ESRX) with regards to formulary management, and believes that if CVS provides a 5-year outlook in December, shares will likely rally. Larsen reiterates an Outperform rating and $110 rating on CVS' shares.
08/15/16
LEER
08/15/16
NO CHANGE
LEER
Outperform
Leerink more positive on CVS after Formulary exclusions lists
Leerink analyst David Larsen says he's incrementally more positive on CVS Health (CVS) after the company and Express Scripts (ESRX) published their 2017 National Preferred Formulary exclusions lists. CVS is being more aggressive about using bio-similar products and has excluded about 10 products due to hyperinflation trends, Larsen tells investors in a research note. Express Scripts is excluding around 85 products in 2017, which is almost half of the 153 products being excluded by CVS, the analyst writes. He keeps an Outperform rating on CVS and a Market Perform ration on Express Scripts.
08/29/16
LEER
08/29/16
NO CHANGE
LEER
EpiPen price is Mylan's issue, says Leerink
Leerink analyst David Larsen says the recent weakness in pharmacy benefit managers and the drug distribution group is "overdone," as he believes Mylan (MYL) has been taking the vast majority of the pricing increases that have occurred with EpiPen, not the pharmacy benefit managers and distributors. Further, the analyst estimates that Cardinal Health (CAH) has a "fee-for-service" deal with EpiPen, which means that there may be no benefit to the company for any price increase that occurs, and notes that Express Scripts (ESRX) gives back 80%-90% of EpiPen rebates to their plan customers. Larsen would be a buyer of CVS Health (CVS) on weakness.
10/05/16
UBSW
10/05/16
INITIATION
Target $76
UBSW
Neutral
Express Scripts initiated with a Neutral at UBS
Target $76.

TODAY'S FREE FLY STORIES

BBY

Best Buy

$51.15

0.51 (1.01%)

06:42
04/25/17
04/25
06:42
04/25/17
06:42
Upgrade
Best Buy rating change  »

Best Buy upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXE

Anixter

$80.70

1.35 (1.70%)

06:40
04/25/17
04/25
06:40
04/25/17
06:40
Hot Stocks
Anixter raises FY17 organic sales growth to 2%-5% »

The company said "We…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

ACN

Accenture

$119.36

0.13 (0.11%)

06:39
04/25/17
04/25
06:39
04/25/17
06:39
Hot Stocks
Accenture awarded $64M TSA contract »

Accenture Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXE

Anixter

$80.70

1.35 (1.70%)

06:38
04/25/17
04/25
06:38
04/25/17
06:38
Earnings
Anixter reports Q1 adjusted EPS $1.09, consensus 99c »

Reports Q1 revenue $1.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

AZZ

AZZ Inc.

$59.10

2.52 (4.45%)

06:37
04/25/17
04/25
06:37
04/25/17
06:37
Hot Stocks
AZZ Inc. awarded contract from Beijing Sino-American Yuli Power Technology »

AZZ Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$25.33

0.71 (2.88%)

06:37
04/25/17
04/25
06:37
04/25/17
06:37
Earnings
Fifth Third reports Q1 EPS 38c, consensus 37c »

Reports Q1 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MDT

Medtronic

$80.65

0.17 (0.21%)

06:37
04/25/17
04/25
06:37
04/25/17
06:37
Hot Stocks
Medtronic says DCB demonstrates consistent results »

Medtronic reinforced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 06

    Jun

PHM

PulteGroup

$23.08

-0.24 (-1.03%)

06:35
04/25/17
04/25
06:35
04/25/17
06:35
Hot Stocks
PulteGroup reports backlog of 9,323 homes at Q1-end »

For the quarter, net new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 12

    May

GPK

Graphic Packaging

$13.58

0.04 (0.30%)

06:35
04/25/17
04/25
06:35
04/25/17
06:35
Earnings
Graphic Packaging reports Q1 EPS 14c, consensus 12c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    May

EPZM

Epizyme

$14.90

0.35 (2.41%)

06:34
04/25/17
04/25
06:34
04/25/17
06:34
Hot Stocks
FDA grants Fast Track designation to Epizyme's tazemetostat »

Epizyme announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIT

CIT Group

$44.29

0.69 (1.58%)

06:34
04/25/17
04/25
06:34
04/25/17
06:34
Earnings
CIT Group reports Q1 EPS ex-items 80c, consensus 59c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

PHM

PulteGroup

$23.08

-0.24 (-1.03%)

06:34
04/25/17
04/25
06:34
04/25/17
06:34
Hot Stocks
PulteGroup reports Q1 value of net new orders up 16% to $2.4B »

Net New Orders Up 8% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 12

    May

BA

Boeing

$182.06

1.68 (0.93%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

06:33
04/25/17
04/25
06:33
04/25/17
06:33
Periodicals
Boeing nears decision on 737-10 jet launch, Reuters reports »

Boeing (BA) is close to a…

BA

Boeing

$182.06

1.68 (0.93%)

EADSY

Airbus

$20.02

0.84 (4.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 31

    May

PHM

PulteGroup

$23.08

-0.24 (-1.03%)

06:33
04/25/17
04/25
06:33
04/25/17
06:33
Earnings
PulteGroup reports Q1 EPS 28c, consensus 29c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 12

    May

SVU

Supervalu

$3.85

0.01 (0.26%)

06:32
04/25/17
04/25
06:32
04/25/17
06:32
Hot Stocks
Supervalu reports Q4 retail identical store sales down 5.8% »

Total net sales within…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NLSN

Nielsen

$41.59

0.59 (1.44%)

06:32
04/25/17
04/25
06:32
04/25/17
06:32
Earnings
Nielsen sees FY17 GAAP EPS $1.40-$1.46 , consensus $2.68 »

Sees FY17 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

  • 03

    May

  • 31

    May

FBC

Flagstar Bancorp

$28.69

0.31 (1.09%)

06:32
04/25/17
04/25
06:32
04/25/17
06:32
Earnings
Flagstar Bancorp reports Q1 EPS 46c, consensus 38c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 23

    May

NLSN

Nielsen

$41.59

0.59 (1.44%)

06:31
04/25/17
04/25
06:31
04/25/17
06:31
Earnings
Nielsen reports Q1 EPS 20c, consensus 48c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

  • 03

    May

  • 31

    May

SVU

Supervalu

$3.85

0.01 (0.26%)

06:31
04/25/17
04/25
06:31
04/25/17
06:31
Earnings
Supervalu reports Q4 adjusted EPS 13c, consensus 9c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BHI

Baker Hughes

$58.65

0.97 (1.68%)

06:30
04/25/17
04/25
06:30
04/25/17
06:30
Earnings
Baker Hughes reports Q1 adjusted EPS (4c), consensus (21c) »

Reports Q1 revenue $2.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LLY

Eli Lilly

$83.42

1.53 (1.87%)

06:29
04/25/17
04/25
06:29
04/25/17
06:29
Hot Stocks
Eli Lilly backs FY17 EPS view of $4.05-$4.15, consensus $4.11 »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

WHR

Whirlpool

$174.80

3.29 (1.92%)

06:28
04/25/17
04/25
06:28
04/25/17
06:28
Hot Stocks
Whirlpool sees about $300M of raw material inflation in 2017 »

Says had sort-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

CAPR

Capricor Therapeutics

$3.09

0.08 (2.66%)

06:28
04/25/17
04/25
06:28
04/25/17
06:28
Conference/Events
Capricor Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

LLY

Eli Lilly

$83.42

1.53 (1.87%)

06:27
04/25/17
04/25
06:27
04/25/17
06:27
Earnings
Eli Lilly reports Q1 EPS 98c, consensus 96c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

WEGRY

Weir Group

$12.91

0.71 (5.82%)

06:27
04/25/17
04/25
06:27
04/25/17
06:27
Upgrade
Weir Group rating change  »

Weir Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.